Ramin Saghafi, MD
Pulmonary Disease · Douglasville, GANPI 1376770800
Payments from drug & device makers
Across 292 payments — averaging $37.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- GSK$2K
- Boehringer Ingelheim$762
- Sanofi$463
- AstraZeneca$430
- Grifols USA, LLC$365
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,42349%
- Education$5,62051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 5 | $5,530 |
| GSK | 98 | $1,571 |
| Boehringer Ingelheim | 42 | $762 |
| Sanofi | 17 | $463 |
| AstraZeneca | 24 | $430 |
| Grifols USA, LLC | 17 | $365 |
| Regeneron Healthcare Solutions, Inc. | 8 | $208 |
| ANI Pharmaceuticals, Inc. | 9 | $192 |
| Mylan Specialty L.p. | 7 | $135 |
| Actelion Pharmaceuticals US, Inc. | 6 | $128 |
| Pulmonx Corporation | 5 | $111 |
| United Therapeutics Corporation | 4 | $91 |
| AbbVie(2 entities) | 6 | $89 |
| Novartis | 3 | $68 |
| Insmed, Inc. | 3 | $68 |
| Jazz Pharmaceuticals Inc. | 2 | $67 |
| Electromed, Inc. | 5 | $67 |
| Shire North American Group Inc | 3 | $63 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
| Amgen | 3 | $58 |
| Astellas Pharma US Inc | 2 | $55 |
| Mallinckrodt Enterprises LLC | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Baxter Healthcare | 2 | $45 |
| Merck | 2 | $32 |
| Johnson & Johnson | 1 | $30 |
| Sanofi Pasteur Inc. | 1 | $29 |
| Viatris Specialty LLC | 1 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Advanced Respiratory, Inc | 1 | $26 |
| 3b Medical, Inc. | 1 | $26 |
| Boston Scientific | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Pfizer | 1 | $14 |
| Circassia Inc. | 1 | $13 |
| La Jolla Pharmaceutical Company | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,500
- NUCALA$125
How this compares
$11,043 in reported general payments places this provider in the 70th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 391 | $302,537 |
| AdempasRiociguat | 14 | $187,645 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $135,847 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 123 | $64,752 |
| TezspireTezepelumab-Ekko | 11 | $48,518 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 65 | $44,721 |
| Spiriva RespimatTiotropium Bromide | 51 | $33,330 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $30,783 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $20,262 |
| Advair HfaFluticasone Propion/Salmeterol | 43 | $16,242 |
| XareltoRivaroxaban | 13 | $14,140 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 399 | $13,457 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 29 | $13,350 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $10,767 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 48 | $7,349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,571 | $392,306575 claims |
| Grifols USA, LLCProlastin C | $365 | $135,84711 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Bevespi Aerosphere, Symbicort | $430 | $103,418130 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $762 | $78,050116 claims |
| Johnson & JohnsonXarelto | $30 | $14,14013 claims |
| MerckAsmanex | $32 | $1,78911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Douglasville
- Binu GeorgeDouglasville$150K
- Marshaleen KingDouglasville$74K
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.